《Nature,8月31日,Signal amplification by reversible exchange for COVID-19 antiviral drug candidates》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-09-15
  • Signal amplification by reversible exchange for COVID-19 antiviral drug candidates
    Hye Jin Jeong, Sein Min, Heelim Chae, Sarah Kim, Gunwoo Lee, Sung Keon Namgoong & Keunhong Jeong
    Scientific Reports volume 10, Article number: 14290 (2020)

    Abstract
    Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies.

  • 原文来源:https://www.nature.com/articles/s41598-020-71282-6
相关报告
  • 《Nature,5月8日,Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-09
    • Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo Wei Deng, Yanfeng Xu, Qi Kong, Jing Xue, Pin Yu, Jiangning Liu, Qi Lv, Fengdi Li, Qiang Wei & Linlin Bao Signal Transduction and Targeted Therapy volume 5, Article number: 66 (2020) Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly swept through the worldwide, with more than 3 million confirmed cases. Until now, no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection. Existing medicines have some strong advantages on pharmacokinetics, known side effects, safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection.
  • 《8月31日_超极化技术有助于进一步研究COVID-19候选药物的作用》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-09-15
    • 8月31日,Scientific Reports期刊发表了题为“Signal amplification by reversible exchange for COVID-19 antiviral drug candidates”的文章。 文章指出,目前已经提出并测试了几种作为COVID-19最新临床治疗方法的候选药物。科学家正在开展利用氯喹、羟氯喹、利托那韦/洛匹那韦和法匹拉韦等治疗该疾病的试验。超极化技术有助于进一步理解这些药物在分子尺度和核磁共振/磁共振成像领域不同应用中的作用。该技术可能为COVID-19的诊断和研究提供新的机会。研究人员通过基于可逆交换的超极化研究将大分子候选药物的信号放大。研究人员从整个结构中观察到了超极化质子信号,这是因为仲氢的长距离极化转移。研究还发现,最大极化转移产率的最佳磁场取决于分子结构。作者指出,可以期待对其他重要大分子的超极化、同位素标记以及自旋松弛时间较长的核上极化转移开展进一步研究。从临床的角度看药物分子的这些特点,可以拓宽超极化技术在治疗研究中的应用。 原文链接:https://www.nature.com/articles/s41598-020-71282-6